Riskpilot← Back to searchSign inGet full accessLabsystems Diagnostics Oy
OYActiveY-tunnus 2494052-3Tiilitie 3Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2012— employees
Revenue 2025
EUR 9,4M
+17% vs 2024
EBITDA margin
-8.8%
-185% vs 2024
Equity ratio
66.9%
Financial strength
Net profit 2025
EUR -1,3M
-407% vs 2024
| Revenue | EUR 9,4M | +17% |
| EBITDA | EUR -820K | -185% |
| Net profit | EUR -1,3M | -407% |
| Total assets | EUR 9,2M | +74% |
| Equity | EUR 6,1M | -18% |
| Employees | — | — |
Legal name
Labsystems Diagnostics Oy
Y-tunnus number
2494052-3
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22. elokuuta 2012
Share capital
EUR 6 503 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on joko suoraan tai tytäryhtiöidensä välityksellä harjoittaa diagnostiikkatuotteiden kehittämistä, valmistamista, myyntiä ja markkinointia sekä muita niihin liittyviä toimintoja. Yhtiö voi myös omistaa ja hallita kiinteistöjä ja arvopapereita sekä tarjota hallinnollisia, rahoitus- ja muita palveluita muille sen kanssa samaan konserniin kuuluville yhtiöille.
Address
Tiilitie 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 6 152 | 6 383 | 10 602 | 18 575 | 9 122 | 8 029 | 9 366 |
| Staff expenses | −2 058 | −2 059 | −2 175 | −2 695 | −1 912 | −1 949 | −2 041 |
| EBITDA | 1 090 | 1 084 | 3 087 | 5 014 | −801 | 963 | −820 |
| Depreciation & amort. | −2 035 | −1 201 | −1 129 | −1 153 | −1 262 | −497 | −443 |
| EBIT | −944 | −117 | 1 958 | 3 861 | −2 062 | 465 | −1 263 |
| Net financials | −156 | −145 | −96 | 36 | 225 | −31 | −70 |
| Profit before tax | −1 100 | −262 | 1 861 | 3 897 | −1 837 | 435 | −1 334 |
| Tax | −0 | −0 | 647 | 948 | −0 | −0 | −0 |
| Net profit | −1 100 | −262 | 1 214 | 2 949 | −1 837 | 435 | −1 334 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 8 502 | 7 387 | 6 784 | 11 591 | 8 346 | 5 281 | 9 165 |
| Equity | 3 263 | 3 000 | 4 215 | 8 869 | 7 032 | 7 466 | 6 132 |
| Long-term debt | — | 2 028 | — | — | 0 | 0 | 0 |
| Short-term debt | 5 239 | 2 360 | 2 569 | 2 722 | 1 314 | 1 171 | 3 033 |
| Total debt | 5 239 | 4 388 | 2 569 | 2 722 | 1 314 | 1 171 | 3 033 |
EBITDA margin
-8.8%
This company
15.8%
Market median
-156% vs market
20192025
Equity ratio
66.9%
This company
38.2%
Market median
+75% vs market
20192025
Return on equity
-21.7%
This company
18.4%
Market median
-218% vs market
20192025
Net profit margin
-14.2%
This company
8.1%
Market median
-275% vs market
20192025
Asset turnover
1.02×
This company
1.12×
Market median
+9% vs market
20192025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20192025
- Annual report 2025Filed via PRH / YTJ · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via PRH / YTJ · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via PRH / YTJ · Period 2018-04-01 – 2019-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TL Confidential Clerk | Confidential Clerk | 2019 | — | — |
MK | Audit | 2016 | — | — |
EK Confidential Clerk | Confidential Clerk | 2024 | — | — |
HS Audit | Audit | 2021 | — | — |
SM Confidential Clerk | Confidential Clerk | 2019 | — | — |
AP Audit | Audit | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Chairperson | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Labsystems Diagnostics Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Timo Lauri Hietala | Confidential Clerk | 0 companies |
| Mauri Kalevi Eskelinen | Audit | 0 companies |
| Efosa Kevin Eboigbodin | Confidential Clerk | 0 companies |
| Heikki Samuli Mäki | Audit | 0 companies |
| Subramanian Murugan | Confidential Clerk | 0 companies |
| Ari Petri Hakkola | Audit | 0 companies |
| Chandra Ganjoo | Board of Directors | 0 companies |
| Kulandaivelu Gomathybabu Sadacharam | Chairperson | 0 companies |
| Nikhil Ravindra Bedekar | Board of Directors | 0 companies |
| Sameer Dungardas Saral | Board of Directors | 0 companies |